ALBUCHIP Trial Design
Cross-source consensus on ALBUCHIP Trial Design from 1 sources and 4 claims.
1 sources · 4 claims
Other
Other
Highlighted claims
- ALBUCHIP is a randomised, controlled, open-label, parallel-group, multicentre trial conducted in six French centres. — Efficacy of intraoperative use of 20% albumin in combination with Ringer’s lactate versus Ringer’s lactate during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: protocol for a randomised controlled, open-label clinical trial (ALBUCHIP trial)
- Randomisation is centralised, uses computer-generated sequences, and allocates patients 1:1 with stratification by centre. — Efficacy of intraoperative use of 20% albumin in combination with Ringer’s lactate versus Ringer’s lactate during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: protocol for a randomised controlled, open-label clinical trial (ALBUCHIP trial)
- The trial is registered on ClinicalTrials.gov and approved under an EU CT number. — Efficacy of intraoperative use of 20% albumin in combination with Ringer’s lactate versus Ringer’s lactate during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: protocol for a randomised controlled, open-label clinical trial (ALBUCHIP trial)
- The trial does not use a placebo arm because the fluid strategy is unblinded. — Efficacy of intraoperative use of 20% albumin in combination with Ringer’s lactate versus Ringer’s lactate during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: protocol for a randomised controlled, open-label clinical trial (ALBUCHIP trial)